Abstract
Recombinant adenoviral vectors have served as one of the most efficient gene delivery vehicles in vivo thus far. Multiply attenuated or completely gutless adenoviral vectors have been developed to achieve long-term gene expression in animal models by overcoming cellular immunity against de novo synthesized adenoviral proteins. However, since adenovirus lacks native integration machinery, the goal of gene therapy obtaining permanent expression cannot be realized with current adenoviral vector systems. Recent studies have shown that replication-incompetent adenoviral vectors randomly integrate into host chromosomes at frequencies of 0.001-1% of infected cells. To improve the integration frequencies of adenoviral vectors, a variety of hybrid vectors combining the highly efficient DNA delivery of adenovirus with the integrating machinery of retroviruses, adeno-associated viruses, and transposons, have been emerging. These hybrid vectors have shown promise, at least in in vitro systems. Furthermore, a denoviral vectors have shown potential as gene targeting vectors. These developments should eventually lead to more effective gene therapy vectors that can transduce a myriad of cell types stably in vivo.
Keywords: Adenovirus, Integrating Vector, HOST CHROMOSOMES, Colony-forming units
Current Gene Therapy
Title: Adenovirus As An Integrating Vector
Volume: 2 Issue: 2
Author(s): K. Mitani and S. Kubo
Affiliation:
Keywords: Adenovirus, Integrating Vector, HOST CHROMOSOMES, Colony-forming units
Abstract: Recombinant adenoviral vectors have served as one of the most efficient gene delivery vehicles in vivo thus far. Multiply attenuated or completely gutless adenoviral vectors have been developed to achieve long-term gene expression in animal models by overcoming cellular immunity against de novo synthesized adenoviral proteins. However, since adenovirus lacks native integration machinery, the goal of gene therapy obtaining permanent expression cannot be realized with current adenoviral vector systems. Recent studies have shown that replication-incompetent adenoviral vectors randomly integrate into host chromosomes at frequencies of 0.001-1% of infected cells. To improve the integration frequencies of adenoviral vectors, a variety of hybrid vectors combining the highly efficient DNA delivery of adenovirus with the integrating machinery of retroviruses, adeno-associated viruses, and transposons, have been emerging. These hybrid vectors have shown promise, at least in in vitro systems. Furthermore, a denoviral vectors have shown potential as gene targeting vectors. These developments should eventually lead to more effective gene therapy vectors that can transduce a myriad of cell types stably in vivo.
Export Options
About this article
Cite this article as:
Mitani K. and Kubo S., Adenovirus As An Integrating Vector, Current Gene Therapy 2002; 2 (2) . https://dx.doi.org/10.2174/1566523024605591
DOI https://dx.doi.org/10.2174/1566523024605591 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Involvement of the P2X7 Purinergic Receptor in Inflammation: An Update of Antagonists Series Since 2009 and their Promising Therapeutic Potential
Current Medicinal Chemistry Incorporating Link Information in Feature Selection for Identifying Tumor Biomarkers by Using miRNA-mRNA Paired Expression Data
Current Proteomics The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine Detection of Unilateral Hearing Loss by Stationary Wavelet Entropy
CNS & Neurological Disorders - Drug Targets Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Current Cancer Therapy Reviews Diagnostic and Therapeutic Applications of Exosome Nanovesicles in Lung Cancer: State-of-The-Art
Anti-Cancer Agents in Medicinal Chemistry Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Smart Mesoporous Silica Nanocarriers for Antitumoral Therapy
Current Topics in Medicinal Chemistry Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine Editorial [Hot topic: Current Formulations and Techniques of Drug/gene Delivery for Targeted Therapy and Tissue Engineering (Executive Editors: Chi-Hwa Wang and Sudhir H. Ranganath)]
Current Pharmaceutical Design Andrographolide Inhibits Osteopontin Expression and Breast Tumor Growth Through Down Regulation of PI3 Kinase/Akt Signaling Pathway
Current Molecular Medicine Synthesis and Biological Evaluation of Novel 2-imino-4-thiazolidinones as Potential Antitumor Agents for Glioblastoma
Medicinal Chemistry Current Status and Perspectives in the Development of Camptothecins
Current Pharmaceutical Design Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme
Current Medicinal Chemistry Recent Progress in Stimuli-Responsive Intelligent Nano Scale Drug Delivery Systems: A Special Focus Towards pH-Sensitive Systems
Current Drug Targets Critical Steps in Tissue Processing in Histopathology
Recent Patents on DNA & Gene Sequences Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design